Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells

A method for treating or preventing cancer or neoplastic disease in a patient, comprising administering to a patient in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof having the following features:

• (a) a hydrogen bond donor feature, D1;
• (b) a hydrogen bond acceptor feature, A1;
• and
• (c) a polar group feature, P1;
• wherein said D1, A1 and P1 each has a centroid, each centroid being separated by the distances:
• 16 Pair of features Distance between the features A1-D1 2.5-4.5 Å P1-D1 4.5-6.5 Å P1-A1 2.5-4.5 Å.

A method for treating or preventing cancer or neoplastic disease in a patient, comprising administering to a patient in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof having the following features:

• (a) a heterocyclic aromatic ring, Ring A;
• (b) a heterocyclic aromatic ring, Ring B, substituted with a polar group;
• (c) a heterocyclic aromatic ring, Ring C;
• (d) an aliphatic group:
• wherein said heterocyclic aromatic ring, Ring A;
• heterocyclic aromatic ring, Ring B, substituted with a polar group;
• heterocyclic aromatic ring, Ring C;
• and aliphatic group, each have a centroid, each centroid being separated by the distances:
• 17 Range of Distances Features Between Features (Å) heterocyclic aromatic ring (ring A);
• 1.5-4.0 heterocyclic aromatic ring (ring B) substituted with a polar group heterocyclic aromatic ring (ring B) 2.5-5 substituted with a polar group;
• heterocyclic aromatic ring (ring C) heterocyclic aromatic ring (ring B) 4.0-6.5 substituted with a polar group;
• aliphatic group heterocyclic aromatic ring (ring A);
• 4.0-6.5 aliphatic group heterocyclic aromatic ring (ring C);
• 3.5-6.5 aliphatic group

A method of treating or preventing cancer or neoplastic disease, comprising administering to a patient in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof having the following features:

• (a) a first hydrogen bond donor feature, D1;
• (b) a hydrogen bond acceptor feature, A1;
• (c) a second hydrogen bond donor feature, D2;
• and
• (d) a polar group feature, P1;
• wherein said D1, A1, D2 and P1 each has a centroid, each centroid being separated by the distances:
• 18 Pair of features Distance between the features A1-D1 2.5-4.5 Å A1-D2 2.5-4.5 Å D1-D2 3.5-5.5 Å P1-D1 4.5-6.5 Å P1-A1 2.5-4.5 Å P1-D2 4.5-6.5 Å.

A method for treating or preventing cancer or neoplastic disease in a patient, comprising administering to a patient in need thereof an effective amount of a compound of Formula III:

• A—B—X—C (III)
• or a pharmaceutically acceptable salt thereof,
• wherein:
• A is selected from the group consisting of
• 36
• and optionally substituted at one or more carbon atoms with one or more —C1-C6, —OC1-C6, —OC(O)C1-C6, —C(O)C1-C6, —C(O)OC1-C6, —CF3, —NO2, —CH2O—C1-C6, or halo groups;
• R1 is selected from the group consisting of H, —C1-C6 and —C(O)C1-C6;
• B is selected from the group consisting of
• 37
• and optionally substituted at one or more carbon atoms with one or more —C1-C6, —OC1-C6, —OC(O)C1-C6, —C(O)C1-C6, —C(O)OC1-C6, —CF3, —NO2, —CH2O—C1-C6, or halo groups.
• X is selected from the group consisting of —O—, —S— and —N(H)—;
• and
• C is selected from the group consisting of
• 38
• and optionally substituted at one or more carbon atoms with one or more —C1-C6, —OC1-C6, —OC(O)C1-C6, —C(O)C1-C6, —C(O)OC1-C6, —CF3, —NO2, —CH2O—C1-C6, or halo groups.

A method for inhibiting the growth of a cancer cell or neoplastic cell comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or a pharmaceutically acceptable salt thereof having the following features:

• (a) a first hydrogen bond donor feature, D1;
• (b) a hydrogen bond acceptor feature, A1;
• and
• (c) a second hydrogen bond donor feature, D2;
• wherein said D1, A1 and D2 each has a centroid, each centroid being separated by the distances:
• 19 Pair of features Distance between the features A1-D1 2.5-4.5 Å A1-D2 2.5-4.5 Å D1-D2 3.5-5.5 Å.

A method for inhibiting the growth of a cancer cell or neoplastic cell comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or a pharmaceutically acceptable salt thereof having the following features:

• (a) a hydrogen bond donor feature, D1;
• (b) a hydrogen bond acceptor feature, A1;
• and
• (c) a polar group feature, P1;
• wherein said D1, A1, and P1 each has a centroid, each centroid being separated by the distances:
• 20 Pair of features Distance between the features A1-D1 2.5-4.5 Å P1-D1 4.5-6.5 Å P1-A1 2.5-4.5 Å

A method for inhibiting the growth of a cancer cell or neoplastic cell comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or a pharmaceutically acceptable salt thereof having the following features:

• (a) a heterocyclic aromatic ring, Ring A;
• (b) a heterocyclic aromatic ring, Ring B, substituted with a polar group;
• (c) a heterocyclic aromatic ring, Ring C;
• (d) an aliphatic group:
• wherein said heterocyclic aromatic ring, Ring A;
• heterocyclic aromatic ring, Ring B substituted with a polar group;
• heterocyclic aromatic ring, Ring C;
• and aliphatic group, each have a centroid, each centroid being separated by the distances:
• 21 Range of Distances Features Between Features (Å) heterocyclic aromatic ring (ring A);
• 1.5-4.0 heterocyclic aromatic ring (ring B) substituted with a polar group heterocyclic aromatic ring (ring B) 2.5-5 substituted with a polar group;
• heterocyclic aromatic ring (ring C) heterocyclic aromatic ring (ring B) 4.0-6.5 substituted with a polar group;
• aliphatic group heterocyclic aromatic ring (ring A);
• 4.0-6.5 aliphatic group heterocyclic aromatic ring (ring C);
• 3.5-6.5 aliphatic group

A method for inhibiting the growth of a cancer cell or neoplastic cell comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound or a pharmaceutically acceptable salt thereof having the following features:

• (a) a first hydrogen bond donor feature, D1;
• (b) a hydrogen bond acceptor feature, A1;
• (c) a second hydrogen bond donor feature, D2;
• and
• (d) a polar group feature, P1;
• said D1, A1, D2 and P1 each has a centroid, each centroid being separated by the distances:
• 22 Pair of features Distance between the features A1-D1 2.5-4.5 Å A1-D2 2.5-4.5 Å D1-D2 3.5-5.5 Å P1-D1 4.5-6.5 Å P1-A1 2.5-4.5 Å P1-D2 4.5-6.5 Å.

A method for inhibiting the growth of a cancer cell or a neoplastic cell comprising contacting the cancer cell or neoplastic cell with an effective amount of a compound of Formula III:

• A—B—X—C (III)
• or a pharmaceutically acceptable salt thereof,
• wherein:
• A is selected from the group consisting of
• 39
• and optionally substituted at one or more carbon atoms with one or more —C1-C6, —OC1-C6, —OC(O)C1-C6, —C(O)C1-C6, —C(O)OC1-C6, —CF3, —NO2, —CH2O—C1-C6, or halo groups;
• R1 is selected from the group consisting of H, —C1-C6 and —C(O)C1-C6;
• B is selected from the group consisting of
• 40
• and optionally substituted at one or more carbon atoms with one or more —C1-C6, —OC1-C6, —OC(O)C1-C6, —C(O)C1-C6, —C(O)OC1-C6, —CF3, —NO2, —CH2O—C1-C6, or halo groups,
• X is selected from the group consisting of —O—, —S— and —N(H)—;
• and
• C is selected from the group consisting of
• 41
• and optionally substituted at one or more carbon atoms with one or more —C1-C6, —OC1-C6, —OC(O)C1-C6, —C(O)C1-C6, —C(O)OC1-C6, —CF3, —NO2, —CH2O—C1-C6, or halo groups.